Study of Gardasil in Mid-Adult Males (MAM)

Phase 2

Completed

Brief Summary: The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus \[HPV\] infection in men (HIM) Study.

Detailed Description: The MAM Study is a prospective pilot intervention trial to investigate patterns of human papillomavirus (HPV) vaccine immunogenicity in men, aged 27-45 years, in which the men will receive Gardasil. Gardasil was administered at 0, 2, and 6 months. Blood was drawn at 0 and 7 months to provide a quadrivalent HPV antibody serologic profile. Participants also completed surveys via computer-assisted interviews (CASI) at Day 1 and Month 7 to record sexual behavior.

Our overall goal is to test the efficacy of Gardasil to reduce HPV 6, 11, 16, 18 persistent infection among men at the external genital epithelium, anal canal, and oral cavity, and to reduce lesions caused by these HPV types at the external genital epithelium and anal canal. The purpose of this Phase II trial is to establish the immunogenicity of Gardasil among mid-adult men and to establish the infrastructure with which to build the larger Phase III trial in the future.

Recruitment & Eligibility

Inclusion Criteria

Men that have completed 4 years of follow-up in the on-going international prospective natural history study of HPV in men (The HIM Study)
Willing to comply with 4 scheduled visits within a 7-month period

Exclusion Criteria

Have received an HPV vaccine
Have a prior diagnosis of penile or anal cancers
Have a prior diagnosis of high grade anal intraepithelial neoplasia
Have been diagnosed with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
Have a history of anaphylaxis to vaccines
Have known impairment of the immune system
Have received any blood products within 6 months of enrollment

Arm && Interventions

Group	Intervention	Description
Gardasil Vaccine	Gardasil	Vaccine Administration: A total of 3 injections (shots) at 3 separate visits.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Seropositive at Month 7	7 Months	Immune response was measured with a multiplex competitive Luminex immunoassay (anti-HPV-6, -11, -16, and -18 chemiluminescence immunoassay analyzer (cLIA); Merck) at Pharmaceutical Product Development (PPD). Briefly, this assay simultaneously quantitates neutralizing antibodies to HPV 6, 11, 16, and 18 in 50 μL of serum. The seronegative study population at Day 1 (no detectable HPV antibody titers at Day 1) were to be categorized as seroconverted due to increase in titer levels for each vaccine component at Month 7.

Secondary Outcome Measures

Name	Time	Method
Change in Antibody Titers	Points: Day 1 and Month 7	Change in antibody titers 1 month post-dose 3 of vaccine. For each vaccine component, the geometric mean titers (GMT) and the corresponding 95% confidence intervals (CI) were calculated for antibody titers at each time-point (Day 1 and Month 7). For each participant, the difference in antibody titers between these 2 time-points (titers at Month 7 minus titers at Day 1) was calculated. The mean of antibody titer change and its 95% CI were calculated. Immune response was measured with a multiplex competitive Luminex immunoassay (anti-HPV-6, -11, -16, and -18 chemiluminescence immunoassay analyzer (cLIA); Merck) at Pharmaceutical Product Development (PPD). Briefly, this assay simultaneously quantitates neutralizing antibodies to HPV 6, 11, 16, and 18 in 50 μL of serum. mMU/ml is an arbitrary unit of measure derived after comparing relative inhibition of mAb-PE binding to a pooled standard reference serum using a four-parameter logistic curve fit and correcting for dilution.

Locations (2): National Institute of Public Health, Mexico
🇲🇽
Cuernavaca, Mexico
H. Lee Moffitt Cancer Center and Research Institute
🇺🇸
Tampa, Florida, United States